Snow Software Surpasses $100 Million in Annual Recurring Revenue
Snow Software, the global leader in technology intelligence, today announced it surpassed $100 million in annual recurring revenue (ARR). Fueled by skyrocketing cloud adoption, increasing security threats and the need to optimize IT budgets, Snow started the year with 40% year-over-year growth in total ACV bookings driven by 115% growth in subscription ACV bookings. These milestones were achieved as Snow successfully pivoted to a recurring revenue business model, now at 75% recurring revenue and growing, and remains on track to positive EBITDA in 2020.
“As organizations accelerate their reliance on cloud, complex hybrid environments are the new reality for many IT leaders, and Snow sits at the nexus of this transformation,” said Vishal Rao, President and Chief Executive Officer at Snow. “Crossing $100 million ARR reaffirms that visibility, optimization and governance across all technology is a strategic priority for the enterprise. Of course, we would not have been able to achieve this milestone without the continuous support of our customers and partners. Today, we serve Global 2000 companies in healthcare, finance, energy, defense and more – the trust that organizations like NASA, Nordstrom, ING, Dyson and Vodafone have placed in us is humbling. By providing a flexible platform of best-in-class solutions for managing software, SaaS, hardware and cloud, we are uniquely positioned to deliver long-term value for the world’s largest organizations.”
Snow has continued to double down on innovation to address the growing market need for asset management, cost optimization and risk mitigation both on-premises and in the cloud. Over the past year, Snow has deepened its SaaS capabilities to include advanced functionality for essential workplace tools such as Office 365 and Adobe Creative Suite as well as remote work staples such as Zoom, GoToMeeting and WebEx, driving its SaaS product to 500% year-over-year ACV bookings growth. Snow also acquired the leading hybrid cloud management company Embotics, and has seen strong demand for its award-winning Commander cloud management platform from both prospects and existing customers.
“Now, more than ever, it’s essential that companies optimize IT spend, minimize risks and increase governance over technology investments,” said Mike Risman, Chairman of the Board at Snow and Managing Partner at Vitruvian. “When we first invested in Snow, they were the dominant players in the European market with a strong focus on software asset management. Over the past two years, they have truly transformed the business to meet the needs of today’s IT leaders. Snow has now achieved global scale as a platform player with unmatched breadth and depth. We are thrilled to continue working with the team as they deliver on Snow’s bold vision for technology intelligence.”
Analysts and industry experts continue to recognize Snow. In 2020, Snow was named a Leader in the Gartner Magic Quadrant for Cloud Management Platforms1 for the second year in a row. Snow was also a finalist in both the ITAM Review Excellence Awards and SIIA CODIE Awards. This follows a strong 2019, where Snow was recognized as a Leader in the Gartner Magic Quadrant for Software Asset Management Tools2 for the second year in a row. In addition to analyst and industry recognition, Snow was named a 2019 Gartner Peer Insights Customers’ Choice in Software Asset Management Tools for the third time.
1 Gartner, “Magic Quadrant for Cloud Management Platforms” by Dennis Smith, Sanjit Ganguli, Padraig Byrne. February 13, 2020. Snow was positioned as Snow Software-Embotics.
2 Gartner, “Magic Quadrant for Software Asset Management Tools” by Roger Williams, Matt Corsi, Ryan Stefani, April 24, 2019.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
About Snow Software
Snow Software is the global leader in technology intelligence solutions, ensuring the trillions spent on all forms of technology is optimized to drive maximum value. More than 4,000 organizations around the world rely on Snow's platform to provide complete visibility, optimize usage and spend, and minimize regulatory risk. Headquartered in Stockholm, Snow has more local offices and regional support centers than any other software asset and cloud management provider, delivering unparalleled results to our customers and partners. To find out more about Snow Software, visit www.snowsoftware.com.
For the latest information about Snow, please visit:
Web:www.snowsoftware.com
Twitter: @snowsoftware
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005625/en/
Contact information
Julie Neumann
Snow Software
julie.neumann@snowsoftware.com
+1 615 498 9650
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom